Download Supplemental Material Description

Pathological complete response in TNBC with platinum-taxane combination chemotherapy
1
Supplemental Material
Participating institutions for the Spanish MMJ-CAR-2014-01 cohort: Hospital G. U.
Gregorio Marañón (Madrid, Spain), Hospital Clínico San Carlos (Madrid, Spain),
Hospital de la Santa Creu I Sant Pau (Barcelona, Spain), Hospital VallD´Hebron
(Barcelona, Spain), Instituto Nacional de Enfermeda des Neoplásicas (Lima, Perú),
Hospital de la Princesa (Madrid, Spain), and Hospital Clínico Universitario de Valladolid
(Valladolid, Spain).
Details on local guidelines for positive family history
KU cohort: >1 first- second- or third-degree blood relative with breast cancer at age <50
years, or>1 first- second- or third-degree blood relative with epithelial ovarian cancer at
any age 1.
Spanish MMJ-CAR-2014-01 cohort: families with ≥3 women with breast cancer
independent of age or ≥2 women with breast cancer with one < 51 years, or ≥1 woman
affected by breast and 1 by ovarian cancer or ≥1 woman affected by breast and ovarian
cancer or at least two women affected by ovarian cancer or at least one woman affected
by bilateral breast cancer with first breast cancer at < 51 years, or ≥1 woman affected
by breast cancer <36 years, or ≥1 man affected by breast cancer and one additional
relative affected by breast or ovarian cancer in one side of the family 2,3.
Neoadjuvant platinum - taxane combination chemotherapy in TNBC
Supplemental Table 1. Pathological response and Family history of breast and ovarian
cancer
Positive Family history*
Negative Family history
P**
N=50
N=131
pCR
N (%) (95% CI)
N (%) (95% CI)
Yes
27 (54%) (40%, 68%)
72 (55%) (46%, 64%)
1.0
No
23 (46%) (32%, 60%)
59 (45%) (36%, 54%)
RCB 0+1
N (%) (95% CI)
N (%) (95% CI)
Yes
38 (76%) (64%, 88%)
85 (65%) (57%, 73%)
0.21
No
12 (24%) (12%, 36%)
46 (35%) (27%, 43%)
*Utilizing cohort specific definitions of positive family history as outlined in patient characteristics
section. ** Fisher Exact test.
Supplemental Table 2. Pathological response by ER/PR
pCR
Yes
No
RCB 0+1
Yes
No
*Fisher Exact test.
s
ER/PR = 0%
N=177
ER/PR <10%
N=6
97 (55%)
80 (45%)
3 (50%)
3 (50%)
1.0
121 (67%)
56 (33%)
4 (67%)
2 (33%)
1.0
P*
2
Neoadjuvant platinum - taxane combination chemotherapy in TNBC
Supplement Table 3. Predictors of RCB 0+1 on univariate
analysis
OR
95% CI
P*
Age
<50
1
>50
0.98
0.53, 1.83
1.0
LN status
Negative
1
Positive
0.43
0.22, 0.81
0.01
T stage
T1/2
1
T3/4
0.27
0.14,0.51
<0.001
TNM stage
I/ II
1
III
0.28
0.5, 0.55
< 0.001
gBRCA mutation
Negative/unknown 1
Positive
1.12
0.46, 2.73
1.0
Family History
No
1
Yes
1.71
0.82, 3.60
0.21
Cohort
Spanish
1
KU
2.72
1.34, 5.54
0.005
*Odds ratios (ORs) and 2-sided P values by Fisher’s exact test.
REFERENCES
1.
Sharma P, Klemp JR, Kimler BF, et al: Germline BRCA mutation evaluation in a
prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian
cancer syndrome testing. Breast Cancer Res Treat 145:707-14, 2014
2.
Meindl A, Ditsch N, Kast K, et al: Hereditary breast and ovarian cancer: new genes, new
treatments, new concepts. Dtsch Arztebl Int 108:323-30, 2011
3.
Schmutzler S: Diagnosis and Treatment of Patients with Primary and Metastatic Breast
Cancer, Breast Cancer Risk and Prevention, AGO e.V. in der DGGG e.V. sowie in der DKG e.V., 2015
s
3